| Identification | Back Directory | [Name]
L-Alanine, L-tyrosyl-L-alanyl-L-arginyl-L-alanyl-L-alanyl-L-alanyl-L-arginyl-L-glutaminyl-L-alanyl-L-arginyl-L-alanyl-L-lysyl-L-alanyl-L-leucyl-L-alanyl-L-arginyl-L-glutaminyl-L-leucylglycyl-L-valyl-L-alanyl- | [CAS]
1039342-24-9 | [Synonyms]
MMI-0100
L-Alanine, L-tyrosyl-L-alanyl-L-arginyl-L-alanyl-L-alanyl-L-alanyl-L-arginyl-L-glutaminyl-L-alanyl-L-arginyl-L-alanyl-L-lysyl-L-alanyl-L-leucyl-L-alanyl-L-arginyl-L-glutaminyl-L-leucylglycyl-L-valyl-L-alanyl- | [Molecular Formula]
C98H171N37O26 | [MOL File]
1039342-24-9.mol | [Molecular Weight]
2283.64 |
| Chemical Properties | Back Directory | [density ]
1.46±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C, protect from light, stored under nitrogen | [form ]
Solid | [color ]
White to off-white | [Water Solubility ]
Water : 100 mg/mL (43.79 mM; Need ultrasonic) |
| Hazard Information | Back Directory | [Uses]
MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease[1]. | [in vivo]
MMI-0100 (100 μM; 28 days) inhibits intimal hyperplasia in a mouse vein graft model[1]. | Animal Model: | 12-week-old C57Bl/6 wild type mice (intimal hyperplasia)[1] | | Dosage: | 100 μM | | Administration: | vein graft, 28 days | | Result: | Diminished wall thickness at all postoperative time points in vein grafts treated with MMI-0100, with a ratio of 2.6-fold thicker at 4 weeks, compared to 4.7-fold thicker at 4 weeks in control grafts. |
| [storage]
Store at -20°C, protect from light, stored under nitrogen | [References]
[1] Akihito Muto, et al. Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. Vascul Pharmacol. Jan-Feb 2012;56(1-2):47-55. DOI:10.1016/j.vph.2011.07.008 |
|
|